02.03.2010 • NewsCarbogen AmcisDishmanRoche

Carbogen Amcis Names Dr. Mojmir Vavrecka Chief Operating Officer

Switzerland-based Carbogen Amcis, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, has appointed Dr. Mojmir Vavrecka as chief operating officer. In his new role, Dr. Vavrecka will oversee manufacturing activities and technology development. He will report directly to Nick Green, president of the global contract research and manufacturing services (CRAMS) for Dishman Pharmaceuticals and Chemicals, Carbogen Amcis' parent company.

Dr. Vavrecka has more than 18 years of experience in the pharmaceutical sector and has a strong academic background in synthetic organic chemistry. Previously, Dr. Vavrecka served as site director for SAFC Phama, UK, overseeing manufacturing, project management, process development and quality control. Prior to this appointment, he served as head of chemical production for Fluka, Switzerland and worked for Hoffmann La Roche as plant and validation manager. He also holds a Ph.D. in chemistry from the University of Zürich.

The addition of Dr. Vavrecka follows Carbogen Amcis' November expansion of late phase service offerings and high-potency manufacturing at its Swiss sites.

Company

Dishman Europe Ltd.

120 New Cavendish St.
W1W 6XX London

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.